First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Accent Therapeutics
Accent Therapeutics
Pheon Therapeutics
Tempus AI
Institut Bergonié
Alaunos Therapeutics
Mayo Clinic
NantCell, Inc.
NextCure, Inc.
ADC Therapeutics S.A.
Milton S. Hershey Medical Center
pharmaand GmbH
MacroGenics
CureOne
Novartis
University of Utah
National Cancer Institute (NCI)
Calando Pharmaceuticals
National Cancer Institute (NCI)
Cancer Research UK
Vanderbilt-Ingram Cancer Center
Mayo Clinic